Tags

Type your tag names separated by a space and hit enter

Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Clin Genitourin Cancer. 2016 Apr; 14(2):e143-52.CG

Abstract

BACKGROUND

Prostate cancer is a common and aggressive cancer among men. Despite advances in treatment, the mechanisms involved in progression are still unclear. New prognostic markers are needed to better design patient-specific therapeutic regimens.

MATERIALS AND METHODS

The present study included 120 patients: 76 with prostate carcinoma, 12 with low-grade prostate intraepithelial lesions, 12 with high-grade prostate intraepithelial lesions, and 20 with benign prostatic hyperplasia. Immunohistochemical study was performed for Golgi phosphoprotein-3 (GOLPH3) and Y-box-binding protein-1 (YB-1) analysis. The correlation with clinicopathologic data and overall survival was analyzed.

RESULTS

Both GOLPH3 and YB-1 showed increased expression from benign to malignant tumors. In prostate carcinoma, cytoplasmic GOLPH3 was associated with Gleason score, tumor stage, and androgen receptor status (P = .034, P < .001, and P = .008, respectively). Nuclear YB-1 expression was associated with Gleason score and androgen receptor status (P = .018 and P = .024, respectively). Cytoplasmic YB-1 expression was associated with Gleason score, tumor stage, and androgen receptor status (P = .008, P = .027, and P < .001, respectively). A high Gleason score (P = .004), high tumor stage (P < .001), and androgen receptor-independent cancer (P = .006) were the only detected adverse prognostic clinicopathologic factors. Moderate to intense GOLPH3 and high nuclear and cytoplasmic YB-1 expression correlated with shorter overall survival (P < .001, P = .020, and P < .001, respectively). On multivariate analysis, moderate to intense GOLPH3 expression was the only predictor of overall survival (P = .025).

CONCLUSION

High GOLPH3 and nuclear/cytoplasmic YB-1 expression correlated with a poor prognosis in patients with prostate cancer. Both markers could be promising targets for new treatment strategies.

Authors+Show Affiliations

Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt. Electronic address: nehadreda@ymail.com.Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt.Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt.Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt.Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26794392

Citation

Abd El-Maqsoud, Nehad M R., et al. "Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer." Clinical Genitourinary Cancer, vol. 14, no. 2, 2016, pp. e143-52.
Abd El-Maqsoud NM, Osman NA, Abd El-Hamid AM, et al. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer. Clin Genitourin Cancer. 2016;14(2):e143-52.
Abd El-Maqsoud, N. M., Osman, N. A., Abd El-Hamid, A. M., Fath El-Bab, T. K., & Galal, E. M. (2016). Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer. Clinical Genitourinary Cancer, 14(2), e143-52. https://doi.org/10.1016/j.clgc.2015.12.015
Abd El-Maqsoud NM, et al. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer. Clin Genitourin Cancer. 2016;14(2):e143-52. PubMed PMID: 26794392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer. AU - Abd El-Maqsoud,Nehad M R, AU - Osman,Nisreen A A, AU - Abd El-Hamid,Amr M A, AU - Fath El-Bab,Tarek K, AU - Galal,Ehab M, Y1 - 2015/12/24/ PY - 2015/07/09/received PY - 2015/12/13/revised PY - 2015/12/16/accepted PY - 2016/1/23/entrez PY - 2016/1/23/pubmed PY - 2016/12/15/medline KW - BPH KW - GOLPH3 KW - PIN KW - Prostate cancer KW - YB-1 SP - e143 EP - 52 JF - Clinical genitourinary cancer JO - Clin Genitourin Cancer VL - 14 IS - 2 N2 - BACKGROUND: Prostate cancer is a common and aggressive cancer among men. Despite advances in treatment, the mechanisms involved in progression are still unclear. New prognostic markers are needed to better design patient-specific therapeutic regimens. MATERIALS AND METHODS: The present study included 120 patients: 76 with prostate carcinoma, 12 with low-grade prostate intraepithelial lesions, 12 with high-grade prostate intraepithelial lesions, and 20 with benign prostatic hyperplasia. Immunohistochemical study was performed for Golgi phosphoprotein-3 (GOLPH3) and Y-box-binding protein-1 (YB-1) analysis. The correlation with clinicopathologic data and overall survival was analyzed. RESULTS: Both GOLPH3 and YB-1 showed increased expression from benign to malignant tumors. In prostate carcinoma, cytoplasmic GOLPH3 was associated with Gleason score, tumor stage, and androgen receptor status (P = .034, P < .001, and P = .008, respectively). Nuclear YB-1 expression was associated with Gleason score and androgen receptor status (P = .018 and P = .024, respectively). Cytoplasmic YB-1 expression was associated with Gleason score, tumor stage, and androgen receptor status (P = .008, P = .027, and P < .001, respectively). A high Gleason score (P = .004), high tumor stage (P < .001), and androgen receptor-independent cancer (P = .006) were the only detected adverse prognostic clinicopathologic factors. Moderate to intense GOLPH3 and high nuclear and cytoplasmic YB-1 expression correlated with shorter overall survival (P < .001, P = .020, and P < .001, respectively). On multivariate analysis, moderate to intense GOLPH3 expression was the only predictor of overall survival (P = .025). CONCLUSION: High GOLPH3 and nuclear/cytoplasmic YB-1 expression correlated with a poor prognosis in patients with prostate cancer. Both markers could be promising targets for new treatment strategies. SN - 1938-0682 UR - https://www.unboundmedicine.com/medline/citation/26794392/Golgi_Phosphoprotein_3_and_Y_Box_Binding_Protein_1_Are_Novel_Markers_Correlating_With_Poor_Prognosis_in_Prostate_Cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1558-7673(15)00345-6 DB - PRIME DP - Unbound Medicine ER -